Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
December 08, 2022 07:00 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
November 10, 2022 16:05 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
November 07, 2022 07:30 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 04, 2022 07:00 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
October 11, 2022 16:01 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
September 19, 2022 16:01 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
September 14, 2022 20:07 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
In der HARMONY-Studie der Phase 2b von Akero Therapeutics wurde in der 50-mg- und der 28-mg-EFX-Dosisgruppe nach 24 Wochen statistische Signifikanz bei primären und sekundären histologischen Endpunkten erzielt
September 14, 2022 07:18 ET
|
Akero Therapeutics
In den Gruppen mit 50 mg (41 %) und 28 mg (39 %) wurde im Vergleich zu Placebo (20 %) eine doppelt so hohe Anzahl von Patienten mit mindestens einstufiger Verbesserung der Fibrose ohne...
Dans l'étude HARMONY de phase 2b d'Akero Therapeutics, les doses de 50 mg et 28 mg d'EFX ont atteint la signification statistique sur les critères d'évaluation histologique primaires et secondaires après 24 semaines
September 14, 2022 07:18 ET
|
Akero Therapeutics
Les groupes recevant 50 mg (41 %) et 28 mg (39 %) ont affiché une amélioration d'au moins 1 stade de la fibrose sans aggravation de la NASH, le double par rapport au placebo (20 %) Les groupes...
Akero Therapeutics Announces Proposed Public Offering of Common Stock
September 13, 2022 16:01 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...